You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫藥業(002422.SZ):注射用頭孢唑林鈉/氯化鈉注射液獲得藥品註冊批准
格隆匯 06-12 18:36

格隆匯6月12日丨科倫藥業(002422.SZ)公佈,公司子公司湖南科倫製藥有限公司的化學藥品“注射用頭孢唑林鈉/氯化鈉注射液”於近日獲得國家藥品監督管理局的藥品註冊批准。頭孢唑林鈉是抗感染治療的經典用藥,目前臨牀廣泛用於各種手術圍術期預防用藥和治療敏感菌所致的呼吸道、皮膚軟組織、骨關節等感染,也是WHO唯一認定用於手術預防的首選頭孢菌素,已被《WHO:AWaRe抗生素手冊(2023)》《國家抗微生物治療指南(第三版)(2022)》《中國循證指南:圍手術期感染的預防與管理(2023)》等國內外權威指南廣泛推薦。注射用頭孢唑林鈉/氯化鈉注射液為國家醫保乙類品種,2024年頭孢唑林鈉注射劑中國銷售13.5億元。公司注射用頭孢唑林鈉/氯化鈉注射液為國內第2家獲批粉液雙室袋包裝形式。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account